Theodore M Brasky1,2, Geoffrey C Kabat3, Gloria Y F Ho4, Cynthia A Thomson5, Wanda K Nicholson6, Wendy E Barrington7, Marisa A Bittoni8,9, Sylvia Wassertheil-Smoller10, Thomas E Rohan10. 1. Division of Cancer Prevention and Control, The Ohio State University College of Medicine, Columbus, OH, USA. Theodore.Brasky@osumc.edu. 2. The Ohio State University-James Comprehensive Cancer Center, 1590 N. High St., Suite 525, Columbus, OH, 43201, USA. Theodore.Brasky@osumc.edu. 3. , New Rochelle, USA. 4. Department of Occupational Medicine, Epidemiology & Prevention, Feinstein Institute for Medical Research, Hofstra Northwell School of Medicine, Great Neck, NY, USA. 5. Health Promotion Sciences Department, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA. 6. Department of Obstetrics & Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 7. Department of Psychosocial & Community Health, School of Nursing, University of Washington, Seattle, WA, USA. 8. The Ohio State University-James Comprehensive Cancer Center, 1590 N. High St., Suite 525, Columbus, OH, 43201, USA. 9. James Thoracic Center, Division of Medical Oncology, The Ohio State University College of Medicine, Columbus, OH, USA. 10. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
BACKGROUND: Obesity is a chronic inflammatory condition strongly associated with the risk of numerous cancers. We examined the association between circulating high-sensitivity C-reactive protein (hsCRP), a biomarker of inflammation and strong correlate of obesity, and the risk of three understudied obesity-related cancers in postmenopausal women: ovarian cancer, kidney cancer, and multiple myeloma. METHODS: Participants were 24,205 postmenopausal women who had measurements of baseline serum hsCRP (mg/L) in the Women's Health Initiative (WHI) CVD Biomarkers Cohort, a collection of four sub-studies within the WHI. Incident cancers were identified over 17.9 years of follow-up (n = 153 ovarian, n = 110 kidney, n = 137 multiple myeloma). hsCRP was categorized into study-specific quartiles. Adjusted Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations of baseline hsCRP with the risk of these cancers. RESULTS: There was no clear association between baseline hsCRP concentration and the risk of ovarian cancer (quartile 4 vs. 1: HR 0.87, 95% CI 0.56-1.37), kidney cancer (HR 0.95, 95% CI 0.56-1.61), or multiple myeloma (HR 0.82, 95% CI 0.52-1.29). HRs for 1 mg/L increases in hsCRP also approximated the null value for each cancer. CONCLUSIONS: The results of this study suggest that elevated CRP is not a major risk factor for these obesity-related cancers (ovarian or kidney cancers, or multiple myeloma) among postmenopausal women. Given the importance of elucidating the mechanisms underlying the association of obesity with cancer risk, further analysis with expanded biomarkers and in larger or pooled prospective cohorts is warranted.
BACKGROUND:Obesity is a chronic inflammatory condition strongly associated with the risk of numerous cancers. We examined the association between circulating high-sensitivity C-reactive protein (hsCRP), a biomarker of inflammation and strong correlate of obesity, and the risk of three understudied obesity-related cancers in postmenopausal women: ovarian cancer, kidney cancer, and multiple myeloma. METHODS:Participants were 24,205 postmenopausal women who had measurements of baseline serum hsCRP (mg/L) in the Women's Health Initiative (WHI) CVD Biomarkers Cohort, a collection of four sub-studies within the WHI. Incident cancers were identified over 17.9 years of follow-up (n = 153 ovarian, n = 110 kidney, n = 137 multiple myeloma). hsCRP was categorized into study-specific quartiles. Adjusted Cox regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations of baseline hsCRP with the risk of these cancers. RESULTS: There was no clear association between baseline hsCRP concentration and the risk of ovarian cancer (quartile 4 vs. 1: HR 0.87, 95% CI 0.56-1.37), kidney cancer (HR 0.95, 95% CI 0.56-1.61), or multiple myeloma (HR 0.82, 95% CI 0.52-1.29). HRs for 1 mg/L increases in hsCRP also approximated the null value for each cancer. CONCLUSIONS: The results of this study suggest that elevated CRP is not a major risk factor for these obesity-related cancers (ovarian or kidney cancers, or multiple myeloma) among postmenopausal women. Given the importance of elucidating the mechanisms underlying the association of obesity with cancer risk, further analysis with expanded biomarkers and in larger or pooled prospective cohorts is warranted.
Authors: Tao Wang; Thomas E Rohan; Marc J Gunter; Xiaonan Xue; Jean Wactawski-Wende; Swapnil N Rajpathak; Mary Cushman; Howard D Strickler; Robert C Kaplan; Sylvia Wassertheil-Smoller; Philipp E Scherer; Gloria Y F Ho Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-03-17 Impact factor: 4.254
Authors: Brenda M Birmann; Marian L Neuhouser; Bernard Rosner; Demetrius Albanes; Julie E Buring; Graham G Giles; Qing Lan; I-Min Lee; Mark P Purdue; Nathaniel Rothman; Gianluca Severi; Jian-Min Yuan; Kenneth C Anderson; Michael Pollak; Nader Rifai; Patricia Hartge; Ola Landgren; Lawrence Lessin; Jarmo Virtamo; Robert B Wallace; JoAnn E Manson; Graham A Colditz Journal: Blood Date: 2012-10-16 Impact factor: 22.113
Authors: Katriina Heikkilä; Ross Harris; Gordon Lowe; Ann Rumley; John Yarnell; John Gallacher; Yoav Ben-Shlomo; Shah Ebrahim; Debbie A Lawlor Journal: Cancer Causes Control Date: 2008-08-15 Impact factor: 2.506
Authors: Sophia N Karagiannis; Aida Santaolalla; Sam Sollie; Ali Rislan; Debra H Josephs; Niklas Hammar; Goran Walldius; Hans Garmo; Mieke Van Hemelrijck Journal: BMC Immunol Date: 2021-09-06 Impact factor: 3.615
Authors: Cilie C Van't Klooster; Paul M Ridker; Jesper Hjortnaes; Yolanda van der Graaf; Folkert W Asselbergs; Jan Westerink; Joachim G J V Aerts; Frank L J Visseren Journal: Eur Heart J Date: 2019-12-21 Impact factor: 29.983